食管癌、胃癌、结肠癌、直肠癌、肝癌、胰腺癌、肺癌与卵巢癌患者的化疗使用情况:国际癌症基准合作组织(ICBP)基于人群的研究
该基于人群的研究利用挪威、英国四地区、加拿大八省和澳大利亚两州的数据,纳入2012年1月1日至2017年12月31日新诊断八种癌症的781892例患者,分析诊断前31天至诊断后365天化疗使用及启动时间的辖区差异。结果显示所有癌种化疗使用率均存在大的辖区间变异,卵巢癌汇总估计66.4%,肝癌16.1%,85-99岁患者化疗使用几率较65-74岁低20倍(OR 0.05,95% PI 0.01-0.19)。
要点
- 所有癌种化疗使用率均存在大的辖区间变异,95%预测区间宽。
- 卵巢癌汇总使用率66.4%,肝癌仅16.1%。
- 85-99岁患者化疗使用几率较65-74岁低20倍(OR 0.05,95% PI 0.01-0.19)。
核心结论
- 参与辖区间化疗使用及启动时间存在大变异,且年龄组差异大且可变,需确立这些模式的原因以指导改善患者结局。
研究设计与样本
- 基于人群的研究,使用挪威、英国四地区、加拿大八省和澳大利亚两州的数据,纳入2012年1月1日至2017年12月31日新诊断八种癌症的781892例患者。
- 信息来自与临床或患者管理系统数据或医院管理数据链接的癌症登记记录。
- 采用随机效应Meta分析量化辖区间变异,使用95%预测区间(95% PI)。
主要发现
- 卵巢癌化疗使用率汇总估计66.4%(95% PI 47.5-81.2)。
- 食管癌47.2%(95% PI 34.9-59.8),直肠癌40.8%(95% PI 22.3-62.3),胃癌39.6%(95% PI 25.7-55.5),胰腺癌34.1%(95% PI 17.2-56.3),肺癌31.4%(95% PI 17.9-49.0),结肠癌29.7%(95% PI 18.6-43.8),肝癌16.1%(95% PI 3.5-50.7)。
- 3期结肠癌患者辖区间变异大于所有结肠癌患者(95% PI 38.5-78.4;汇总估计60.1%)。
- 85-99岁患者化疗使用几率较65-74岁低20倍(OR 0.05;95% PI 0.01-0.19),该年龄差异的辖区间变异很大。
- 直肠癌首次化疗中位时间辖区间变异大(95% PI -15.5至193.9天;汇总估计89.2天);85-99岁患者首次化疗中位时间较65-74岁略短(-3.7天,95% PI -7.6至0.1)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are few data on international variation in chemotherapy use, despite it being a key treatment type for some patients with cancer. Here, we aimed to examine the presence and size of such variation. METHODS: This population-based study used data from Norway, the four UK nations (England, Northern Ireland, Scotland, and Wales), eight Canadian provinces (Alberta, British Columbia, Manitoba, Newfoundland and Labrador, Nova Scotia, Ontario, Prince Edward Island, and Saskatchewan), and two Australian states (New South Wales and Victoria). Patients aged 15-99 years diagnosed with cancer in eight different sites (oesophageal, stomach, colon, rectal, liver, pancreatic, lung, or ovarian cancer), with no other primary cancer diagnosis occurring from within the 5 years before to 1 year after the index cancer diagnosis or during the study period were included in the study. We examined variation in chemotherapy use from 31 days before to 365 days after diagnosis and time to its initiation, alongside related variation in patient group differences. Information was obtained from cancer registry records linked to clinical or patient management system data or hospital administration data. Random-effects meta-analyses quantified interjurisdictional variation using 95% prediction intervals (95% PIs). FINDINGS: Between Jan 1, 2012, and Dec 31, 2017, of 893 461 patients with a new diagnosis of one of the studied cancers, 111 569 (12·5%) did not meet the inclusion criteria, and 781 892 were included in the analysis. There was large interjurisdictional variation in chemotherapy use for all studied cancers, with wide 95% PIs: 47·5 to 81·2 (pooled estimate 66·4%) for ovarian cancer, 34·9 to 59·8 (47·2%) for oesophageal cancer, 22·3 to 62·3 (40·8%) for rectal cancer, 25·7 to 55·5 (39·6%) for stomach cancer, 17·2 to 56·3 (34·1%) for pancreatic cancer, 17·9 to 49·0 (31·4%) for lung cancer, 18·6 to 43·8 (29·7%) for colon cancer, and 3·5 to 50·7 (16·1%) for liver cancer. For patients with stage 3 colon cancer, the interjurisdictional variation was greater than that for all patients with colon cancer (95% PI 38·5 to 78·4; 60·1%). Patients aged 85-99 years had 20-times lower odds of chemotherapy use than those aged 65-74 years, with very large interjurisdictional variation in this age difference (odds ratio 0·05; 95% PI 0·01 to 0·19). There was large variation in median time to first chemotherapy (from diagnosis date) by cancer site, with substantial interjurisdictional variation, particularly for rectal cancer (95% PI -15·5 to 193·9 days; pooled estimate 89·2 days). Patients aged 85-99 years had slightly shorter median time to first chemotherapy compared with those aged 65-74 years, consistently between jurisdictions (-3·7 days, 95% PI -7·6 to 0·1). INTERPRETATION: Large variation in use and time to chemotherapy initiation were observed between the participating jurisdictions, alongside large and variable age group differences in chemotherapy use. To guide efforts to improve patient outcomes, the underlying reasons for these patterns need to be established. FUNDING: International Cancer Benchmarking Partnership (funded by the Canadian Partnership Against Cancer, Cancer Council Victoria, Cancer Institute New South Wales, Cancer Research UK, Danish Cancer Society, National Cancer Registry Ireland, The Cancer Society of New Zealand, National Health Service England, Norwegian Cancer Society, Public Health Agency Northern Ireland on behalf of the Northern Ireland Cancer Registry, DG Health and Social Care Scottish Government, Western Australia Department of Health, and Public Health Wales NHS Trust).
引用
- McPhail S, Barclay ME, Johnson SA, et al. Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study. Lancet Oncol. 2024. PMID: 38423048. doi:10.1016/S1470-2045(24)00031-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。